HYD1 Peptides as Anti-Cancer Agents
    2.
    发明申请
    HYD1 Peptides as Anti-Cancer Agents 失效
    HYD1肽作为抗癌剂

    公开(公告)号:US20080108552A1

    公开(公告)日:2008-05-08

    申请号:US11852177

    申请日:2007-09-07

    CPC分类号: G01N33/5011 C07K7/06

    摘要: The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as myeloma. The present invention further includes a method of increasing the efficacy of chemotherapy and radiation therapy, comprising administering an agent that binds β1 integrin to a patient in need thereof. In one embodiment, the β1 integrin binding agent is the HYD1 peptide, or a functional fragment or variant thereof. In another aspect, the invention pertains to a composition (an adhesion trap) comprising a substrate (also referred to as a surface or support) with a HYD1 peptide, or fragment or variant thereof, immobilized to the substrate, and a method of removing circulating tumor cells (CTC) from blood by contacting a subject's blood with the immobilized peptide. Another aspect of the invention concerns a method of identifying modulators of peptide binding. Another aspect of the invention concerns a method for detecting CTC.

    摘要翻译: 本发明涉及HYD1肽的片段和变体; 编码肽的多核苷酸; 用多核苷酸遗传修饰的宿主细胞; 包含多核苷酸的载体; 含有这些肽,多核苷酸,载体或宿主细胞的组合物; 以及使用肽,多核苷酸,载体和宿主细胞作为体外或体内异常细胞生长的抑制剂的方法,例如用作治疗癌症如骨髓瘤的抗癌剂。 本发明进一步包括增加化学疗法和放射治疗功效的方法,其包括向有需要的患者施用结合β1整联蛋白的药剂。 在一个实施方案中,β1整联蛋白结合剂是HYD1肽或其功能片段或变体。 另一方面,本发明涉及一种组合物(粘附陷阱),其包含固定在基底上的HYD1肽或其片段或变体的底物(也称为表面或载体),以及除去循环的方法 通过使受试者的血液与固定的肽接触,从血液中获得肿瘤细胞(CTC)。 本发明的另一方面涉及鉴定肽结合调节剂的方法。 本发明的另一方面涉及一种检测CTC的方法。

    Method of preparing coded compound libraries
    3.
    发明申请
    Method of preparing coded compound libraries 审中-公开
    编码化合物库的方法

    公开(公告)号:US20060134697A1

    公开(公告)日:2006-06-22

    申请号:US11261842

    申请日:2005-10-28

    申请人: Kit Lam Xiaobing Wang

    发明人: Kit Lam Xiaobing Wang

    IPC分类号: C40B40/02

    CPC分类号: C07K1/047

    摘要: The present invention relates to methods of preparing a library of compounds, wherein each of the compounds resides on the exterior portion and is encoded by coding tags confined in each of successive zones on the interior portion of a solid support. Following screening of the compounds, the coding tags can be cleaved, and then characterized by mass spectrometry.

    摘要翻译: 本发明涉及制备化合物文库的方法,其中每个化合物位于外部部分,并通过编码限制在固体支持物内部的每个连续区域中的标签进行编码。 在筛选化合物之后,编码标签可以被切割,然后通过质谱法进行表征。

    Methods of oligosaccharide profiling for the detection of cancer
    4.
    发明申请
    Methods of oligosaccharide profiling for the detection of cancer 有权
    寡糖分析方法用于检测癌症

    公开(公告)号:US20060035304A1

    公开(公告)日:2006-02-16

    申请号:US11157478

    申请日:2005-06-20

    IPC分类号: C12Q1/34

    摘要: The present invention provides methods for identifying oligosaccharides specific to cancer and methods for determining a strain of cancer in an individual. The present invention also provides methods for diagnosing cancer or a stage of cancer in an individual by detecting the presence or absence of specific cancer markers and methods for treating cancer by administering antibodies directed to such markers. In addition, the present invention provides cancer markers comprising O-linked oligosaccharides and kits for diagnosing or treating cancer.

    摘要翻译: 本发明提供用于鉴定癌症特异性的寡糖的方法和用于确定个体中癌症菌株的方法。 本发明还提供了通过检测针对这种标记的抗体来检测特异性癌症标志物的存在或不存在以及用于治疗癌症的方法来诊断个体癌症或癌症阶段的方法。 此外,本发明提供包含O-连接的寡糖的癌症标志物和用于诊断或治疗癌症的试剂盒。

    Alpha-4 beta-1 integrin ligands for imaging and therapy
    5.
    发明申请
    Alpha-4 beta-1 integrin ligands for imaging and therapy 有权
    用于成像和治疗的α-4β-1整联蛋白配体

    公开(公告)号:US20060019900A1

    公开(公告)日:2006-01-26

    申请号:US11140548

    申请日:2005-05-26

    摘要: The present invention provides α4β1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.

    摘要翻译: 本发明提供了表现出高结合亲和力,特异性和稳定性的α4AT1A整联蛋白配体。 配体包含具有n个独立选择的氨基酸的肽,其中至少一个氨基酸是非天然氨基酸或D-氨基酸,并且其中n是3-20的整数。提供了用于给予 治疗癌症,炎性疾病和自身免疫性疾病。 还提供了用于施用用于成像受试者的肿瘤,器官或组织的配体的方法。

    HYD1 peptides as anti-cancer agents
    6.
    发明授权
    HYD1 peptides as anti-cancer agents 失效
    HYD1肽作为抗癌剂

    公开(公告)号:US07632814B2

    公开(公告)日:2009-12-15

    申请号:US11852177

    申请日:2007-09-07

    IPC分类号: A61K38/00

    CPC分类号: G01N33/5011 C07K7/06

    摘要: The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as myeloma. The present invention further includes a method of increasing the efficacy of chemotherapy and radiation therapy, comprising administering an agent that binds β1 integrin to a patient in need thereof. In one embodiment, the β1 integrin binding agent is the HYD1 peptide, or a functional fragment or variant thereof. In another aspect, the invention pertains to a composition (an adhesion trap) comprising a substrate (also referred to as a surface or support) with a HYD1 peptide, or fragment or variant thereof, immobilized to the substrate, and a method of removing circulating tumor cells (CTC) from blood by contacting a subject's blood with the immobilized peptide. Another aspect of the invention concerns a method of identifying modulators of peptide binding. Another aspect of the invention concerns a method for detecting CTC.

    摘要翻译: 本发明涉及HYD1肽的片段和变体; 编码肽的多核苷酸; 用多核苷酸遗传修饰的宿主细胞; 包含多核苷酸的载体; 含有这些肽,多核苷酸,载体或宿主细胞的组合物; 以及使用肽,多核苷酸,载体和宿主细胞作为体外或体内异常细胞生长的抑制剂的方法,例如用作治疗癌症如骨髓瘤的抗癌剂。 本发明进一步包括增加化学疗法和放射治疗功效的方法,其包括向有需要的患者施用结合β1整联蛋白的药剂。 在一个实施方案中,β1整联蛋白结合剂是HYD1肽或其功能片段或变体。 另一方面,本发明涉及一种组合物(粘附陷阱),其包含固定在基底上的HYD1肽或其片段或变体的底物(也称为表面或载体),以及除去循环的方法 通过使受试者的血液与固定的肽接触,从血液中获得肿瘤细胞(CTC)。 本发明的另一方面涉及鉴定肽结合调节剂的方法。 本发明的另一方面涉及一种检测CTC的方法。

    On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
    7.
    发明申请
    On-demand cleavable linkers for radioconjugates for cancer imaging and therapy 审中-公开
    用于癌症成像和治疗的放射性缀合物的按需可切割接头

    公开(公告)号:US20050255042A1

    公开(公告)日:2005-11-17

    申请号:US10997759

    申请日:2004-11-23

    CPC分类号: A61K51/1093

    摘要: The present invention provides compositions comprising a biological agent, a targeting moiety, and a peptide linker attaching the biological agent to the targeting moiety, wherein the peptide linker is selectively cleaved by a protease. Efficient methods are provided for administering the compositions of the present invention for treating cancer or imaging a tumor, organ, or tissue in a subject. Kits are also provided for administering the compositions of the present invention for radiotherapy or radioimaging.

    摘要翻译: 本发明提供了包含生物试剂,靶向部分和将生物试剂连接到靶向部分的肽接头的组合物,其中肽接头被蛋白酶选择性地切割。 提供了有效的方法来施用本发明的治疗癌症或成像受试者的肿瘤,器官或组织的组合物。 还提供了用于将本发明的组合物用于放射治疗或放射成像的试剂盒。